- Home
- OPI vs MBRX Comparison
OPI vs MBRX Comparison
Compare OPI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- MBRX
- Stock Information
- Founded
- OPI 2009
- MBRX 2015
- Country
- OPI United States
- MBRX United States
- Employees
- OPI N/A
- MBRX N/A
- Industry
- OPI Real Estate Investment Trusts
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- OPI Real Estate
- MBRX Health Care
- Exchange
- OPI Nasdaq
- MBRX Nasdaq
- Market Cap
- OPI 16.6M
- MBRX 17.1M
- IPO Year
- OPI 2009
- MBRX 2016
- Fundamental
- Price
- OPI $0.22
- MBRX $0.57
- Analyst Decision
- OPI
- MBRX Strong Buy
- Analyst Count
- OPI 0
- MBRX 3
- Target Price
- OPI N/A
- MBRX $5.33
- AVG Volume (30 Days)
- OPI 596.9K
- MBRX 2.5M
- Earning Date
- OPI 07-30-2025
- MBRX 08-12-2025
- Dividend Yield
- OPI 17.95%
- MBRX N/A
- EPS Growth
- OPI N/A
- MBRX N/A
- EPS
- OPI N/A
- MBRX N/A
- Revenue
- OPI $466,972,000.00
- MBRX N/A
- Revenue This Year
- OPI N/A
- MBRX N/A
- Revenue Next Year
- OPI N/A
- MBRX N/A
- P/E Ratio
- OPI N/A
- MBRX N/A
- Revenue Growth
- OPI N/A
- MBRX N/A
- 52 Week Low
- OPI $0.18
- MBRX $0.25
- 52 Week High
- OPI $2.48
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- OPI 42.18
- MBRX 43.74
- Support Level
- OPI $0.23
- MBRX $0.54
- Resistance Level
- OPI $0.25
- MBRX $0.61
- Average True Range (ATR)
- OPI 0.01
- MBRX 0.05
- MACD
- OPI -0.00
- MBRX -0.01
- Stochastic Oscillator
- OPI 12.00
- MBRX 14.53
About OPI Office Properties Income Trust of Beneficial Interest
Office Properties Income Trust is a United States-based real estate investment trust. Its property portfolio is mainly composed of single-tenant office buildings, as well as multitenant properties, which are leased to parties of high credit quality characteristics. Its major tenant is the U.S. government, followed by other smaller government entities and corporations. The company's properties are spread across the United States. The company has only one segment which is direct ownership of real estate properties.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.